Champions Oncology, Inc., a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc., a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership. Cyclica is an OBIO® member and presented at the OBIO Investment Summit.
The partnership will combine two therapeutic targets identified and validated within Champions’ Lumin platform with Cyclica’s drug discovery platform to establish a new therapeutic program. The planned partnership will initiate with a single program focused on previously unexplored targets present in tumor indications such as non-small cell lung cancer, head and neck cancer, and other solid tumors. The partnership will also leverage the unique experimental platforms available at Champions to ensure rapid and efficient development towards clinical evaluation. Under the terms of this agreement, Champions will co-own the program with Cyclica and take lead in advancing the program, and, upon achievement of specified milestones and events, will be obligated to make milestone and royalty payments to Cyclica. Should Champions decide not to continue development, Cyclica has the option to carry forward the program in exchange for milestone and royalty payments to Champions.